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NMDA receptor (NMDAR) dysfunction has emerged as a common theme in several major nervous system
disorders, including ischemic brain injury, chronic neurodegenerative diseases, pain, depression and
schizophrenia. Either hyperactivity or hypofunction of NMDARs could contribute to disease patho-
physiology. It is likely that distinct subtypes of NMDARs (as deﬁned by subunit composition and/or
subsynaptic location) are differentially involved in central nervous system diseases. Here we focus on a
few examples of nervous system diseases where the contribution of NMDARs is relatively well charac-
terized and discuss the implications for potential treatment of these illnesses.
This article is part of the Special Issue entitled ‘Glutamate Receptor-Dependent Synaptic Plasticity’.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license. NMDA (N-methyl-D-aspartate) receptors (NMDARs) are a sub-
class of glutamate receptors that requires both binding of glutamate
and postsynaptic depolarization for their activation, and that me-
diates Ca2þ entry when they are activated. NMDAR dysfunction e
arising from altered receptor-channel activity, subunit expression,
trafﬁcking, or localization e may contribute to a variety of neuro-
logical and psychiatric conditions. In fact, many nervous system
diseases are now considered to be associated with, or even caused
by, synaptic dysfunction. It has become increasingly clear that
detrimental effects can arise from either hyperactivity or hypo-
function of NMDARs.
Altered NMDAR presence/functions can contribute to central
nervous system (CNS) disease in different ways: their excessive
activation could cause neuronal death, as in stroke and perhaps in
Huntington’s disease, or their reduced activity could alter the bal-
ance of excitation and inhibition in neural circuitry to affect CNS
functions, as likely occurs in schizophrenia. NMDARs are present at
glutamatergic synapses on both excitatory and inhibitory neurons.
Given the differential and often opposite functions of excitatory
versus inhibitory neurons, the functional contributions of these
NMDARs are likely to be different or even opposite. For example,
enhanced NMDAR function on excitatory neurons could lead to
enhanced synaptic plasticity of excitatory neurons, whereas
enhancing NMDARs on inhibitory neurons is likely to boostr Ltd. Open access under CC BY-NC-SAinhibition (reducing excitation as a consequence) and hence reduce
synaptic plasticity of excitatory neurons. Thus, depending on their
locus, altered expression/activity of NMDARs can inﬂuence the
balance between excitation and inhibition and affect circuit
and brain function. At excitatory synapses, the contributions of
NMDARs to CNS diseases may also depend on the subunit
composition and/or the subsynaptic location of these receptors.
This review is not intended to cover the involvement of NMDARs
in every disease of the CNS, but rather to focus on examples where
the contribution of NMDARs is relatively well characterized, and
which might offer insights into treatment of these illnesses.
1. Subunit composition and synaptic location of NMDA
receptors
NMDARs are heterotetramers composed of two GluN1 subunits
(previouslycalledNR1)plus twoGluN2subunits (previouslyknownas
NR2encoded by four different genes GluN2A-D). NMDARs containing
different GluN2A-D subunits exhibit distinct electrophysiological and
pharmacological properties and somewhat different distribution and
expression proﬁles (Cull-Candy and Leszkiewicz, 2004; Paoletti and
Neyton, 2007; Traynelis et al., 2010). For example, NMDARs contain-
ingGluN2AorGluN2Bhave larger single channel conductance, higher
sensitivity to blockade by extracellular Mg2þ and greater Ca2þ
permeability than NMDARs containing GluN2C or GluN2D (Paoletti,
2011). In this review, GluN2A-NMDARs refer to NMDARs that
contain two GluN2A subunits while GluN2B-NMDARs are those that
contain two GluN2B subunits. A signiﬁcant portion of synaptic
NMDARs, however, contain one GluN2A and one GluN2B subunit (the
so-called triheteromeric NMDARs; Sheng et al., 1994; Luo et al., 1997; license. 
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to have properties distinct from the GluN2A-NMDARs and GluN2B-
NMDARs (Neyton and Paoletti, 2006; Rauner and Köhr, 2011), their
contribution to physiological and pathological processes is poorly
deﬁned due to the lack of inhibitors that speciﬁcally block this subset
of NMDARs (Neyton and Paoletti, 2006).
The C-terminal cytoplasmic domains of GluN2A and GluN2B
contain numerous protein interaction and phosphorylation sites
that can affect receptor activity and trafﬁcking (Salter and Kalia,
2004). Although both GluN2A-NMDARs and GluN2B-NMDARs
share some common binding partners (such as postsynaptic den-
sity protein 95 (PSD-95), Sheng and Kim, 2011), they bind differ-
entially to some other proteins. For example, GluN2A-NMDARs
interact with Homer and b-Catenin (Al-Hallaq et al., 2007), whereas
GluN2B-NMDARs bind to Ca2þ/calmodulin-dependent protein ki-
nases II (CaMKII) and synaptic Ras GTPase activating protein
(SynGAP) (Leonard et al., 1999; Kim et al., 2005). The C-terminal
tails of GluN2A and GluN2B may also determine the apparent dif-
ferential roles of GluN2A and GluN2B in excitotoxicity and neuronal
survival (see below).
Activation of NMDARs can be either toxic to neurons or promote
their survival and plasticity. Prolonged exposure of neurons to
glutamate leads to cell death, which is mediated by Ca2þ entry
through NMDARs (Choi, 1987; Rothman and Olney, 1995), in other
words, NMDARs can cause excitotoxicity. On the other hand, activity
of synaptic NMDARs is crucial for the survival of neurons, and
blocking NMDAR activity in vivo, especially during development,
results in neuronal apoptosis (Ikonomidou et al., 1999; Hetman and
Kharebava, 2006). How can these apparently paradoxical actions of
NMDARs be explained? There are two models e localization vs.
subunit composition e to explain the differential contribution of
NMDARs to excitotoxicity and neuronal survival. The “localization
model” (Fig. 1a) posits that activation of extrasynaptic NMDARs is
neurotoxic, whereas activation of synaptic NMDARs is neuro-
protective (Hardinghamet al., 2002;HardinghamandBading, 2010).survival
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Fig. 1. The localization model vs. subunit composition model to account for the differentia
ization model proposes that activation of NMDARs in the extrasynaptic regions (areas outsid
of synaptic NMDARs (in the PSDs, blue) is neuroprotective. b. The subunit composition mode
GluN2A-NMDARs (orange) is neurotrophic. Note that GluN2A-NMDARs are more preferentia
the extrasynaptic regions.Stimulating synaptic NMDARs activates cAMP response element-
binding protein (CREB) signaling and promotes survival, while
activation of extrasynaptic NMDARs attenuates CREB signaling and
promotes cell death (Hardingham and Bading, 2010). The localiza-
tion model relies largely on an operational deﬁnition of extra-
synaptic vs. synaptic location of NMDARs (i.e., extrasynaptic
receptors are those not activated by synaptically released glutamate
but are stimulated by bath-applied glutamate or NMDA)
(Hardingham et al., 2002; Hardingham and Bading, 2010). Due to
technical limitations, most studies on differential roles of synaptic
vs. extrasynaptic NMDARs have been performed in dissociated
cultured neurons. For these reasons, the conclusions reached are not
completely satisfying. This situation could be changed by the recent
work of Papouin et al. (2012) that showed that synaptic and extra-
synaptic NMDARs use D-serine and glycine as their coagonists,
respectively. Thus, by reducing the level of D-serine or glycine with
enzymes that selectively degrade D-amino acids (including D-serine)
or free extracellular glycine, it might be possible to speciﬁcally
control the activation of synaptic or extrasynapticNMDARs inneural
preparations thatmore resembles the in vivo network (such as brain
slices). There is some evidence that D-serine levels are reduced in
certain CNS diseases (e.g., schizophrenia, Labrie et al., 2012). By
selectively reducing the levels of D-serine and/or glycine, it might
then be possible to determine whether alterations in synaptic or
extrasynaptic NMDAR activity could contribute to the pathophysi-
ology of the CNS diseases.
In the “subunit composition model” (Fig. 1b), it is the subunit
make-up of NMDARs that determines whether their activation
has neurotoxic or neuroprotective consequences e activation of
GluN2B-NMDARs is excitotoxic, while activation of GluN2A-
NMDARs is neurotrophic (Lai et al., 2011). Activation of pro-
survival signaling pathways, such as CREB and phosphatidylinosi-
tol 3-kinase (PI3K), has been linked to GluN2A-NMDAR activation,
whereas cell death signaling is more associated with activation of
GluN2B-NMDARs (Liu et al., 2007; Terasaki et al., 2010). Bysurvival
growth
excito-
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l contributions of NMDARs to neuronal survival and excitotoxicity/death. a. The local-
e the PSDs, brown) leads to activation of cell death signaling pathways, while activation
l proposes that activation of GluN2B-NMDARs (green) is excitotoxic, while activation of
lly localized to the synapse, whereas GluN2B-NMDARs are preferentially distributed in
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knock-in mice, it was shown that the cytoplasmic tail of GluN2B is
preferentially coupled to excitotoxicity in neurons, both in vitro and
in vivo (Martel et al., 2012). Studies supporting the subunit
composition model are based on genetic manipulations and phar-
macological tools (which can be applied in in vivo experiments).
However, they suffer from caveats such as confounding secondary
effects of GluN2 gene disruptions (e.g., lethality of GluN2B
knockout) and problematic speciﬁcity of GluN2A-NMDAR antago-
nists. For example, the widely used GluN2A-NMDAR antagonist
NVP-AAM077 has only 10 fold selectivity for GluN2A- over GluN2B-
NMDARs in rodents, and the concentrations used in many studies
inhibit both GluN2A- and GluN2B-NMDARs signiﬁcantly (Berberich
et al., 2005; Weitlauf et al., 2005; Frizelle et al., 2006; Neyton and
Paoletti, 2006).
It should be emphasized that the localization and subunit
composition models are not mutually exclusive since GluN2A and
GluN2B are differentially distributed in neurons. In the adult brain,
GluN2A-NMDARs are largely concentrated within synapses while
GluN2B-NMDARs are largely extrasynaptic (Tovar and Westbrook,
1999; Traynelis et al., 2010). Therefore the localization and sub-
unit composition models are largely overlapping in practice. It is
thus our view that these two models cannot be experimentally
distinguished at this time.
In the following sections of the review, we will summarize the
contributions of NMDARs to the pathophysiology of CNS diseases,
and where appropriate, we will discuss the differential involve-
ment of GluN2A- versus GluN2B-NMDARs, or synaptic versus
extrasynaptic NMDARs. Selective and potent antagonists of
GluN2B-NMDARs allow their contribution to be studied in detail
while the lack of highly selective GluN2A-NMDAR antagonists has
created controversy and contradictory results in the functional
dissection of GluN2A-NMDARs’ roles. In addition, subunit-selective
or -preferring NMDAR antagonists can also inhibit triheteromeric
NMDARs, although likely to a lesser extent than their homomeric
counterparts (Hatton and Paoletti, 2005). These caveats need to be
kept in mind when interpreting the results obtained with NMDAR
antagonists. We will also identify the critical issues that need to be
resolved to advance our understanding of NMDAR involvement in a
particular CNS disease.
2. Stroke and traumatic brain injury (TBI) e excitotoxicity by
NMDARs
It is long known that sustained elevation of extracellular
glutamate results in neuronal death (Lucas and Newhouse, 1957;
Choi, 1987; Rothman and Olney, 1995) and this excitotoxicity con-
tributes to the acute neuronal death seen in stroke and TBI (Bullock
et al., 1998). NMDAR-mediated excitotoxicity may also contribute to
neuronal death in some chronic neurodegenerative diseases, such
as Huntington’s disease (Milnerwood and Raymond, 2010). In
stroke and TBI, NMDAR-dependent excitotoxicity appears to be a
primary cause of neuronal death occurring acutely after ischemia or
injury, and NMDAR blockers protect neurons against ischemic cell
death in vitro and in vivo (Simon et al., 1984; Chen et al., 1991, 2008;
Liu et al., 2007). Interestingly, NMDAR excitotoxicity seems to be
subunit-dependent, since selective GluN2B antagonists blocked,
whereas GluN2A-preferring antagonists exacerbated, ischemic cell
death (Liu et al., 2007; Chen et al., 2008). Thus it is possible that
excessive activation of GluN2B-NMDARs underlies ischemic cell
death whereas activity of GluN2A-NMDARs may promote recovery
after the ischemic insult.
Although results from preclinical studies were promising, clin-
ical trials with NMDAR antagonists in stroke all ended in disap-
pointment (Lai et al., 2011). Among many contributing factors tofailure are intolerable side effects of NMDAR antagonists and the
short therapeutic window for their efﬁcacy e the elevated extra-
cellular glutamate level due to reverse operation of glutamate
transporters during ischemia appears to last less than an hour (Lai
et al., 2011). Consistently, NMDAR antagonists are protective
against ischemic cell death when theywere administered in animal
models prior to (Margaill et al., 1996; Liu et al., 2007; Chen et al.,
2008), but not 30 min (Margaill et al., 1996) or 3 h (Liu et al.,
2007) after the onset of stroke. However, another study showed
that GluN2B antagonist was effective in reducing brain infarct
volumewhen given 2 h after stroke onset (Yang et al., 2003). Rather
than inhibiting the NMDARs themselves, it has also been shown
that disrupting the interactions between NMDARs and their scaf-
folding proteins and associated signaling molecules is also effective
in reducing cell death in stroke models. Binding to GluN2B-
NMDARs by PSD-95, phosphatase and tensin homolog (PTEN) or
death-associated protein kinase 1 (DAPK1) can enhance the activity
of GluN2B-NMDARs and their coupling to downstream cell death
pathways (Aarts et al., 2002; Soriano et al., 2008; Jurado et al., 2010;
Tu et al., 2010). Attempts to disrupt these protein interactions of
NMDARs using synthetic peptides have been reported to reduce
ischemic brain damage in animals (Aarts et al., 2002; Tu et al., 2010;
Cook et al., 2012) and even in humans (Hill et al., 2012).
As in stroke, NMDAR antagonists (including selective GluN2B
antagonists) have failed so far to show any beneﬁt in TBI
(Beauchamp et al., 2008). Although there is clear evidence of
elevated extracellular glutamate level in TBI as in stroke, it is likely
that the elevation of extracellular glutamate (and hence the period
of excitotoxicity) is short-lived and this may contribute to the
failure of NMDAR antagonists in clinical trials. In addition, although
excessive activation of NMDARs is toxic, physiological activation of
NMDARs after TBI may be required for improving functional re-
covery (Biegon et al., 2004). In summary, the involvement of
NMDARs in stroke and TBI is likely to be two-fold e an initial short
period of excessive activation which contributes to cell death and
tissue damage, and a subsequent much longer phase during which
adequate activation of NMDAR is critical for functional recovery.
The critical issue that needs to be resolved is whether GluN2B
antagonists or GluN2B-PSD-95 interaction inhibitors can work in
human cases if treatment is applied early enough after ischemia/
TBI. In addition, it will be of great interest to test whether
enhancing NMDAR function/activity during the recovery phase will
reduce neuronal loss and promote functional recovery.
3. Huntington’s disease (HD)
NMDARs are highly expressed in striatal medium spiny neurons
(MSNs), the major neuronal population in the striatum that de-
generates in HD. Increased levels of extrasynaptic NMDARs inMSNs
are seen in an HD mouse model (YAC128) and their activation ap-
pears to contribute to the vulnerability of MSNs to excitotoxicity
caused by mutant Huntingtin protein (mtHTT; Okamoto et al.,
2009; Milnerwood et al., 2010). Interestingly, activation of synap-
tic NMDARs enhances the formation of non-toxic mtHTT inclusions
and reduces mtHTT-induced toxicity (Okamoto et al., 2009).
Inhibiting NMDARs with a low dose of the non-selective NMDAR
antagonist memantine at ages prior to onset of motor dysfunction
reversed deﬁcits in phosphorylated CREB in the striatum and
rescued performance in a rotarod assay (Okamoto et al., 2009;
Milnerwood et al., 2010). These effects are consistent with the
observation that memantine at low doses preferentially inhibits
extrasynaptic NMDARs (Xia et al., 2010). However, another study
points to a different mode of action for memantine (preferential
inhibition of GluN2C/2D-containing NMDARs than GluN2A/2B-
NMDARs) (Kotermanski and Johnson, 2009).
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NMDARs contribute more to total NMDA-evoked current in D2
dopamine receptor-containing MSNs than in D1-containing MSNs
in a HD mouse model, consistent with the earlier degeneration of
D2 MSNs in HD (Jocoy et al., 2011); and crossing GluN2B-
overexpressing mice with HD model mice exacerbates the death
of MSNs (Heng et al., 2009). Thus, extrasynaptic GluN2B-NMDARs
could play an important role in neuronal cell death in HD. How-
ever, in an R6/2 HD mouse model of HD, high doses of GluN2B
antagonists did not show signiﬁcant beneﬁts on either motor
behavior or animal survival (Tallaksen-Greene et al., 2010). The lack
of efﬁcacy of GluN2B antagonists could be due to antagonists being
administered too late (i.e., after the onset of motor dysfunctions), or
alternatively, antagonists may also block the beneﬁcial effects
mediated by the synaptic GluN2B-NMDARs. Thus, it is important to
determine whether GluN2B antagonists are effective in the YAC128
model, or memantine is effective in the R6/2 model. Besides
memantine (for which there is still debate about whether it
selectively inhibits extrasynaptic NMDARs at low doses), there
appears to be no pharmacologic way to speciﬁcally block extra-
synaptic NMDARs without affecting synaptic NMDARs. Thus, it re-
mains to be established whether GluN2B-NMDARs or extrasynaptic
NMDARs have critical contributions to Huntington disease
pathogenesis.
4. Alzheimer’s disease (AD)
It is widely believed that soluble oligomeric forms of amyloid-b
(Ab) perturb synaptic function and plasticity (Sheng et al., 2012).
Long-term potentiation (LTP) is impaired while long-term depres-
sion (LTD) is facilitated by Ab (Ondrejcak et al., 2010). Downstream
mediators of Ab-induced deﬁcits in LTP may include caspase-3 and
GSK-3b (Jo et al., 2011). Recent studies indicate that Ab-induced
alterations in synaptic function and plasticity require the activation
of GluN2B-NMDARs, as GluN2B antagonists rescued Ab-induced
impairment of LTP (Rönicke et al., 2011; Li et al., 2011b), Ab-induced
loss of synapses and synaptic proteins (Rönicke et al., 2011) (Liu
et al., 2010), Ab-induced facilitation of LTD (Li et al., 2009), and
targeting of Ab to synapses (Deshpande et al., 2009). Further evi-
dence suggests that Ab affects predominantly the extrasynaptic
NMDARs (Li et al., 2009, 2011b), which are largely GluN2B-
containing. However, other studies showed that non-selective
NMDAR antagonists could also block Ab-induced spine loss
(Shankar et al., 2007) and Ab-induced deﬁcits in LTP (Rammes et al.,
2011), leaving open the possibility that activation of NMDARs in
general, rather than GluN2B-NMDARs exclusively, are required for
Ab-induced synaptic dysfunction. Interestingly, the localization of
NMDARs appears to determine their contribution to the production
of Ab. For example, stimulation of synaptic NMDARs increased non-
amyloidgenic processing of APP by alpha-secretase and inhibited
the release of Ab (Hoey et al., 2009); while activation of extra-
synaptic rather than synaptic NMDARs increased neuronal pro-
duction of Ab (Bordji et al., 2010). It needs to be emphasized that
the above evidence supporting NMDAR/GluN2B-NMDARs’ role in
Ab-induced excitotoxicity have largely been obtained using in vitro
preparations and synthetic Ab.
Tau has been shown to be required for localization of fyn tyro-
sine kinase to dendritic spines, where it phosphorylates GluN2B-
NMDARs, thereby enhancing GluN2B-NMDAR association with
PSD-95 and coupling to downstream neurotoxic effects (Ittner
et al., 2010). One intriguing possibility is that conformational
changes in GluN2B-NMDARs, rather than Ca2þ inﬂux through these
receptors mediate the toxic effects of Ab (Malinow, 2012; Ittner
et al., 2010). Furthermore blocking the interaction between
GluN2B and PSD-95 with a synthetic peptide in vivo improvedmemory functions and reduced premature death in ADmice (Ittner
et al., 2010). It is interesting that the same peptide was effective in
reducing neuronal death in stroke models (Aarts et al., 2002). It will
be important to resolve the contribution of GluN2B-NMDARs to AD
by testing whether long-term dosing of GluN2B antagonists is
beneﬁcial in animal models of AD.
5. Pain
Neuropathic pain is a type of chronic pain that occurs following
injury or damage to neurons or nerves in the nervous system.
NMDARs are known to be present in neurons/synapses of the
nociceptive pathway, where NMDARs containing distinct subunit
compositions show differential expression patterns. GluN2B-
NMDARs, but not GluN2A-NMDARs, are present in C-and A-ﬁbers
of the dorsal root ganglia (Marvizón et al., 2002). At the spinal cord
level, GluN2A-NMDARs are present throughout dorsal horn except
in lamina II, while GluN2B-NMDARs appear to be largely absent
from lamina II and restricted to certain areas in the superﬁcial
dorsal horn (Watanabe et al., 1992; Boyce et al., 1999). Both
GluN2A- and GluN2B-NMDARs are widely distributed in the cortex.
NMDARs appear to play an important role in neuropathic pain since
non-selective NMDAR and GluN2B-selective antagonists have been
reported to alleviate neuropathic pain in animals (Wu and Zhuo,
2009; Niesters and Dahan, 2012).
A few key questions need to be resolved regarding the contri-
bution of NMDARs to the development and/or maintenance of
neuropathic pain. The ﬁrst question is subunit composition e
which subtype of NMDARs is involved, GluN2B- or GluN2A-
NMDARs? As discussed above, the distribution of GluN2A-
NMDARs and GluN2B-NMDARs along the nociceptive pathway
appears to be different, suggesting potentially differential contri-
butions from these receptors. In neuropathic pain models, reduced
GluN2A expression (Karlsson et al., 2002) and increased GluN2B
expression (Wilson et al., 2005) in dorsal horn neurons was seen
after nerve injury. Does this mean a shift in the balance between
GluN2A- and GluN2B-NMDARs (toward elevated GluN2B-NMDARs)
could underlie the development of neuropathic pain? Enhanced
phosphorylation of GluN2B at the Tyr1472 site was observed after
induction of neuropathic pain (Abe et al., 2005), while diminished
neuropathic pain was seen in knock-in mice with a mutation pre-
venting phosphorylation of Tyr1472 on GluN2B, which is essential
to their synaptic targeting (Matsumura et al., 2010). Neuropathic
pain is enhanced in knock-in mice with a mutation of GluN2A that
reduces Zn2þ inhibition, thereby elevating GluN2A-NMDAR func-
tion (Nozaki et al., 2011), suggesting that enhanced GluN2A-
NMDAR function could contribute to neuropathic pain. Neverthe-
less, a different study showed that GluN2A knockout mice can still
exhibit neuropathic pain (Abe et al., 2005).
The second critical unresolved question is functional contribu-
tion of NMDARs to pain e are NMDARs enabling the induction of
synaptic plasticity? Enhanced synaptic transmission is associated
with neuropathic pain (Wu and Zhuo, 2009), and one likely
mechanism mediating this enhancement is LTP. LTP of synapses in
the nociceptive pathway has been proposed to be involved in
pathogenesis of neuropathic pain (Sandkühler, 2007). GluN2B-
NMDARs in the spinal cord are required for LTP of C-ﬁber inputs
onto dorsal horn neurons (Pedersen and Gjerstad, 2008; Qu et al.,
2009) and GluN2A- and GluN2B-NMDARs are required for LTP of
cortical inputs to pyramidal neurons in the cingulate cortex (Zhao
et al., 2005). Given that synaptic plasticity is thought to occur
during the initial stages of chronic pain development, this rationale
would predict that the most effective period for NMDAR antago-
nists (including GluN2B antagonists) to treat pain is during the
early stage of pain, as some studies have suggested (Qu et al., 2009).
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the early pain process via LTP is important since clinical trials with
GluN2B antagonists have not yielded conclusive results in treating
pain (Niesters and Dahan, 2012). It is also debatable whether LTP is
required for neuropathic pain at all. LTP in the insulate cortex re-
quires CaMKIV, and CaMKIV KO mice showed impaired LTP but
persistent pain was not altered (Wei et al., 2001), suggesting that
LTP, at least in the insulate cortex which is part of the nociceptive
pathway, is not required for pain.
The last critical question needs to be resolved is the localization
of the NMDARs contributing to pain e are the relevant NMDARs in
the spinal cord or cortex? Qu et al. (2009) reported that GluN2B-
NMDARs in the spinal cord are required for the development of
neuropathic pain while Nakazato et al. (2005) concluded that
GluN2B-NMDARs in the brain are involved in neuropathic pain.
Both studies examined the effects of injecting GluN2B antagonists
into either spinal cord or brain. Resolving the above three questions
will lead to better understanding of the roles played by NMDARs in
neuropathic pain and shed light on whether they are promising
therapeutic targets.
6. Schizophrenia
Traditionally, schizophrenia has been considered a disease of
hyperdopaminergic nature. Although targeting the dopamine sys-
tem is effective in treating positive symptoms, like hallucinations,
this classic hypothesis does not provide a satisfactory account of the
pathophysiology underlying negative symptoms and cognitive
deﬁcits, which are not treated effectively by dopamine receptor
antagonists and which are increasingly recognized as the core
deﬁcits in schizophrenia (Moghaddam and Javitt, 2012; Lewis et al.,
2012). Altered glutamate signaling may provide a better patho-
physiologic basis for schizophrenia.
The glutamate hypothesis or NMDAR hypofunction hypothesis
states that reduced function of glutamatergic synapses, especially of
NMDARsonGABAergic inhibitory interneurons, leads to an imbalance
between excitation and inhibition and perturbations in neural cir-
cuitry that underlie impaired cognitive and executive functions and
ultimately psychosis (Moghaddam and Javitt, 2012). The following
ﬁndings from humans and animal models are consistent with this
hypothesis e (1) NMDAR antagonists cause schizophrenia-like
symptoms in healthy humans, and exacerbate symptoms in schizo-
phrenics (Coyle, 2006). (2) Reduced expression of NMDARs (GluN2A
subunit in particular) has been observed in a subpopulation of
inhibitory neurons (notably those expressing parvalbumin) in post-
mortem samples of schizophrenia patients (Bitanihirwe et al., 2009).
(3) Mice with reduced GluN1 expression showed schizophrenia-like
phenotypes (Mohn et al., 1999). More importantly, many of these
phenotypes could be reproduced in mice with GluN1 selectively
deleted from a sub-population of GABAergic interneurons (the ma-
jority of which contain parvalbumin; Belforte et al., 2010), suggesting
thatdeﬁcientNMDARfunction ina subclassof inhibitory interneurons
may be sufﬁcient to drive the pathophysiology of schizophrenia. In-
hibition of NMDAR function led to decreased expression of parval-
bumin in parvalbumin-containing inhibitory neurons, with GluN2A-
preferring antagonist being more effective than GluN2B antagonist
(Kinney et al., 2006). This reduction in parvalbumin is similar towhat
hasbeenobserved inpost-mortemschizophreniabrain sampleswhile
the density of these parvalbumin-containing neurons is unchanged
(Lewis et al., 2005). Thus, enhancing NMDAR functions could poten-
tially boost the decreased activity/function of inhibitory neurons,
rebalance neural circuitry and improve cognitive functions in
schizophrenia patients.
Clinical trials with glycine or D-serine (which target the glycine
co-agonist site in NMDARs) aiming to enhance the activity andfunction of the glutamate system have produced mixed results
(Coyle, 2006; Lindsley et al., 2006). There are also ongoing efforts to
boost extracellular glycine levels in the brain by inhibiting glycine
uptake with glycine transporter-1 (GlyT-1) inhibitors, thereby
enhancing NMDAR function (Lindsley et al., 2006). However, it is
unknown whether the potential beneﬁts of enhancing NMDAR
function (such as by GlyT-1 inhibitors) in schizophrenia is mediated
by enhanced activation of inhibitory or excitatory neurons. Excit-
atory synapses onto interneurons may have a speciﬁc composition
of NMDAR subtypes (e.g., enriched with GluN2A/2D, Monyer et al.,
1994), raising the possibility that inhibitory neurons could be
selectively targeted by subunit-selective NMDAR modulators.
Regardless of mechanism, one challenge ahead is whether
reversing NMDAR hypofunction in the adult schizophrenic brain is
sufﬁcient to compensate for the malfunctions that might have
accumulated over years during development.
7. Depression
The non-selective NMDAR antagonist ketamine produced rapid
(within hours) and sustained reduction (for days) in depressive
symptoms in human patients with treatment-resistant depression
(Berman et al., 2000; Zarate et al., 2006). The rapid onset is in clear
contrast to traditional antidepressants such as selective serotonin
reuptake inhibitors (SSRIs). In animals, it was found that low doses
of ketamine led to an increase in spine density, enhanced
mammalian target of rapamycin (mTOR) signaling and increased
protein synthesis in the prefrontal cortex, which accompanied the
antidepressant effects (Li et al., 2010). This is consistent with re-
ports of reduced expression of mTOR and its downstream signaling
targets in postmortem brain samples from depressed patients
(Jernigan et al., 2011). Another study also showed that protein
synthesis is required for the fast-acting antidepressant effect of
ketamine in animals but the target identiﬁed was BDNF rather than
mTOR (Autry et al., 2011).
Ketamine reduces the spontaneous activity of GABAergic
inhibitory neurons, which leads to a delayed increase in the activity
of excitatory neurons in conscious rats (Homayoun and
Moghaddam, 2007). Thus one possible target of NMDAR antago-
nists in depression could again be the GABAergic interneurons.
Reducing inhibitory tone could cause immediate effects on the
neural circuitry function (such as enhanced neural activity), which
could set in motion the cellular signaling events that underlie long-
lasting alterations in neural circuitry that mediate antidepressant
effects. Interestingly, in the same animal models, GluN2B antago-
nists triggered similar signaling pathways and also showed anti-
depressant effects (Li et al., 2010, 2011a), suggesting that inhibiting
the activity of GluN2B-NMDARs could account for the majority of
the antidepressant effects of ketamine. As an alternative to
affecting interneuron functions, GluN2B antagonists could exert
their effects by altering the activity of mTOR. In a recent study,
Wang et al. (2011) showed that in genetically modiﬁed mice by
replacing GluN2B with GluN2A, there was an enhanced expression
of synaptic AMPARs via activation of mTOR signaling, which
resembled ketamine-induced changes. Thus, it remains unclear
whether GluN2B antagonists are acting primarily on interneurons
or excitatory neurons (or both) to effect their antidepressant action.
8. Concluding remarks
NMDAR dysfunction is emerging as a common theme in several
major nervous system disorders. Future studies to elucidate how
NMDARs with distinct subunit compositions contribute differen-
tially to nervous system diseases e as well as the speciﬁc sub-
synaptic locations and circuits in which these NMDARs operate e
Q. Zhou, M. Sheng / Neuropharmacology 74 (2013) 69e7574could inform not only about the pathophysiology but also the po-
tential treatment of ischemic brain injury, chronic neurodegener-
ative diseases, pain, depression and schizophrenia.
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